Payment overview · 2025
General Payments
$446.46
25 reported records · 13 companies
Healthcare provider profile · identity verified
Sabih Alam, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DURANT, OK · NPI 1700346350
Verified facts
What the public records show
CMS Open Payments records show Sabih Alam, MD received $446.46 in general payments during 2025 across 25 reported records.
ABBVIE INC. accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.54 | 15.8% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $65.26 | 14.6% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $55.11 | 12.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $48.17 | 10.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.36 | 10.4% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $45.37 | 10.2% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.96 | 4.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.90 | 4.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.92 | 3.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.03 | 3.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.41 | 3.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.21 | 3.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.22 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $446.46 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $65.26 | 3 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $55.11 | 3 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $55.11 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $48.17 | 3 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $46.36 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 107 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
107 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 235 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 224 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 54 |
| Losartan Potassium | Losartan Potassium | 145 | 47 |
| Meloxicam | Meloxicam | 126 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 125 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 40 |
| Ozempic | Semaglutide | 107 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 106 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 98 | 35 |
| Lisinopril | Lisinopril | 98 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 35 |
| Furosemide | Furosemide | 86 | 33 |
| Trazodone Hcl | Trazodone Hcl | 82 | 21 |
| Methylprednisolone | Methylprednisolone | 79 | 69 |
| Pregabalin | Pregabalin | 75 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 24 |
| Temazepam | Temazepam | 73 | 15 |
| Alprazolam | Alprazolam | 68 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 24 |
| Metformin Hcl | Metformin Hcl | 65 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 20 |
| Tramadol Hcl | Tramadol Hcl | 63 | 23 |
| Carvedilol | Carvedilol | 60 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 21 |
| Baclofen | Baclofen | 58 | 14 |
| Eliquis | Apixaban | 54 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 51 | suppressed |
| Prednisone | Prednisone | 51 | 33 |
| Celecoxib | Celecoxib | 50 | 14 |
| Famotidine | Famotidine | 50 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 16 |
| Omeprazole | Omeprazole | 42 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 33 |
| Ondansetron Odt | Ondansetron | 38 | 19 |
| Spironolactone | Spironolactone | 38 | 17 |
| Vraylar | Cariprazine Hcl | 37 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 15 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | 15 |
| Sertraline Hcl | Sertraline Hcl | 31 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | 11 |
| Metformin Hcl Er | Metformin Hcl | 30 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 25 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 16 |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Mupirocin | Mupirocin | 24 | 17 |
| Topiramate | Topiramate | 24 | 11 |
| Cephalexin | Cephalexin | 23 | 20 |
| Finasteride | Finasteride | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | 12 |
| Jardiance | Empagliflozin | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Humira(Cf) Pen | Adalimumab | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $446.46 · 25 records | ABBVIE INC. | ARISTADA, BREZTRI, CAPLYTA, CAPVAXIVE, ENFLONSIA, GARDASIL 9, GEMTESA, INCEPTIV, JOURNAVX, LYBALVI, MAVYRET, Ozempic, PROCLAIM, QULIPTA, ROTATEQ, UBRELVY, VAXNEUVANCE, VOQUEZNA, VRAYLAR, ZENPEP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error